Precision, Novartis ink Potential $1.4B Development Deal | North Carolina Biotechnology Center
Durham-based Precision Biosciences’ genome editing technology has drawn interest – and investment – from another global pharmaceutical giant. This time it’s Novartis.
Source: ncbiotech.org